This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Emerson, D. L. Articles by Baccanari, D. Search for Related Content PubMed PubMed Citation Articles by Emerson, D. L. Articles by Baccanari, D.

Antitumor Efficacy, Pharmacokinetics, and Biodistribution of NX 211: A Low-Clearance Liposomal Formulation of Lurtotecan

Gilead Sciences, Boulder, Colorado 80301 [D. L. E., R. B., E. B., S. C., J. P. D., L. C. D., S. C. G., M .H., J. D. L., L. M-M., K. M., F. C. R., B. T.], and GlaxoWellcome Research Institute, Research Triangle Park, North Carolina, 27709 [M. J. L., D. B.]

Lurtotecan is a clinically active water-soluble camptothecin analogue that has been formulated into a low-clearance unilamellar liposome, NX 211. Comparative studies between free drug and NX 211 have been performed assessing pharmacokinetics in nude mice, tissue distribution in tumor-bearing mice, and antitumor efficacy in xenografts. Compared with lurtotecan, NX 211 demonstrated a significant increase in plasma residence time and a subsequent 1500-fold increase in the plasma area under the drug concentration curve. The volume of distribution was also greatly restricted, suggesting altered tissue distribution. Evaluation of tissues 24 h after administration of either [¹⁴C]NX 211 or [¹⁴C]lurtotecan to ES-2 tumor-bearing mice demonstrated a 40-fold increase in radiolabeled compound in the tumors of NX 211-treated mice compared with mice treated with lurtotecan. In single-dose efficacy studies, NX 211 produced a consistent 3-fold or greater increase in therapeutic index compared with lurtotecan in both the KB and ES-2 xenograft models. When compared at equitoxic levels in repeat-dose efficacy studies, NX 211 generated durable cures lasting >60 days and a 2–8-fold increase in log₁₀ cell kill, compared with lurtotecan and topotecan, respectively. Together, these data demonstrate that NX 211 has significant therapeutic advantage over lurtotecan and that the improved antitumor activity is consistent with increased exposure and enhanced drug delivery to tumor sites.

This article has been cited by other articles:

				D. C. Drummond, C. O. Noble, Z. Guo, K. Hong, J. W. Park, and D. B. Kirpotin Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res., March 15, 2006; 66(6): 3271 - 3277. [Abstract] [Full Text] [PDF]

				G. G. Dark, A. H. Calvert, R. Grimshaw, C. Poole, K. Swenerton, S. Kaye, R. Coleman, G. Jayson, T. Le, S. Ellard, et al. Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., March 20, 2005; 23(9): 1859 - 1866. [Abstract] [Full Text] [PDF]

				K. J. Hamblett, P. D. Senter, D. F. Chace, M. M. C. Sun, J. Lenox, C. G. Cerveny, K. M. Kissler, S. X. Bernhardt, A. K. Kopcha, R. F. Zabinski, et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate Clin. Cancer Res., October 15, 2004; 10(20): 7063 - 7070. [Abstract] [Full Text] [PDF]

				M. J. MacKenzie, H. W. Hirte, L. L. Siu, K. Gelmon, M. Ptaszynski, B. Fisher, and E. Eisenhauer A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers Ann. Onc., April 1, 2004; 15(4): 665 - 670. [Abstract] [Full Text] [PDF]

				D. F.S. Kehrer, A. M. Bos, J. Verweij, H. J. Groen, W. J. Loos, A. Sparreboom, M. J.A. de Jonge, M. Hamilton, T. Cameron, and E. G.E. de Vries Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity J. Clin. Oncol., March 1, 2002; 20(5): 1222 - 1231. [Abstract] [Full Text] [PDF]

				W. J. Loos, J. Verweij, D. F. S. Kehrer, P. de Bruijn, F. M. H. de Groot, M. Hamilton, K. Nooter, G. Stoter, and A. Sparreboom Structural Identification and Biological Activity of 7-Methyl-10,11-Ethylenedioxy-20(S)-Camptothecin, a Photodegradant of Lurtotecan Clin. Cancer Res., March 1, 2002; 8(3): 856 - 862. [Abstract] [Full Text] [PDF]

				F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian Acute Myeloid Leukemia Hematology, January 1, 2002; 2002(1): 73 - 110. [Abstract] [Full Text]